---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-033500"
form_type: "8-K"
ticker: null
cik: "0001850838"
company_name: "Omega Therapeutics, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:24:50.769355+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Omega Therapeutics files Ch. 11, stalking horse asset sale to Flagship affiliate for $11.5M, Nasdaq delisting

## Summary
- Filed Chapter 11 on Feb 10, 2025; entered Stalking Horse APA with PM08-B (Flagship affiliate) for $11.46M credit bid.
- Nasdaq notified delisting due to Chapter 11 filing; trading suspended Feb 25, 2025; Company not appealing.
- Proposed sale process: bid deadline April 1, 2025; auction April 3; sale hearing April 10.
- Company operates as debtor-in-possession under Bankruptcy Court jurisdiction.

## SEC filing metadata
- accession: 0001193125-25-033500
- form_type: 8-K
- cik: 0001850838
- company_name: Omega Therapeutics, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850838/000119312525033500/0001193125-25-033500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850838/000119312525033500/d80395d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-033500
- JSON: https://secwatch.observer/filing/0001193125-25-033500.json
- Plain text: https://secwatch.observer/filing/0001193125-25-033500.txt

## Key facts
- Listing & Compliance Notices
  Omega Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1, 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5101, 5110(b), IM-5101-1, 5450(a)(1)
  source text: February 18, 2025, Company received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq had determined to delist the Company’s common stock, par value $0.001 per share (the “Common Stock”). Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company’s commencement of the Chapter 11 Case on February 10, 2025. The Notice also indicated that concerns about the Company’s ability to sustain compli
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000119312525033500/0001193125-25-033500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.